Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study

BACKGROUND: In preclinical studies trifluridine/tipiracil (FTD/TPI) plus oxaliplatin (Industriestrasse, Holzkirchen, Germany) sensitised microsatellite stable (MSS) metastatic colorectal cancer (mCRC) to anti-programmed cell death protein-1; the addition of oxaliplatin or bevacizumab (F Hoffmann- la...

Descripción completa

Detalles Bibliográficos
Autores principales: Bordonaro, R., Calvo, A., Auriemma, A., Hollebecque, A., Rubovszky, G., Saunders, M.P., Pápai, Z., Prager, G., Stein, A., André, T., Argilés, G., Cubillo, A., Dahan, L., Edeline, J., Leger, C., Cattan, V., Fougeray, R., Amellal, N., Tabernero, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453191/
https://www.ncbi.nlm.nih.gov/pubmed/34547581
http://dx.doi.org/10.1016/j.esmoop.2021.100270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453191/
https://www.ncbi.nlm.nih.gov/pubmed/34547581
http://dx.doi.org/10.1016/j.esmoop.2021.100270

Ejemplares similares